TheraVac Biologics is developing vaccines and immunotherapies for diseases caused by misfolded protein aggregates and/or chronic inflammation. Its vaccines provide a safer and more convenient approach to treat chronic diseases including neurodegenerative conditions such as Alzherimer's. TheraVac’s lead assets include vaccines that target the pathological Tau protein and neuroinflammation. Its vaccines have been tested for safety and efficacy in mouse models of Alzheimer's and non-human primates. TheraVac is fundraising to conduct phase 1 clinical trial.

Event details

Date: June 3 - 6, 2024

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


42 in total